The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Update in Adrenocortical Carcinoma
Abstract
Adrenocortical carcinoma (ACC) is an orphan malignancy that has attracted increasing attention during the last decade. Here we provide an update on advances in the field since our last review published in this journal in 2006. The Wnt/β-catenin pathway and IGF-2 signaling have been confirmed as frequently altered signaling pathways in ACC, but recent data suggest that they are probably not sufficient for malignant transformation. Thus, major players in the pathogenesis are still unknown. For diagnostic workup, comprehensive hormonal assessment and detailed imaging are required because in most ACCs, evidence for autonomous steroid secretion can be found and computed tomography or magnetic resonance imaging (if necessary, combined with functional imaging) can differentiate benign from malignant adrenocortical tumors. Surgery is potentially curative in localized tumors. Thus, we recommend a complete resection including lymphadenectomy by an expert surgeon. The pathology report should demonstrate the adrenocortical origin of the lesion (eg, by steroidogenic factor 1 staining) and provide Weiss score, resection status, and quantitation of the proliferation marker Ki67 to guide further treatment. Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy. In advanced ACC, mitotane is still the standard of care. Based on the FIRM-ACT trial, mitotane plus etoposide, doxorubicin, and cisplatin is now the established first-line cytotoxic therapy. However, most patients will experience progress and require salvage therapies. Thus, new treatment concepts are urgently needed. The ongoing international efforts including comprehensive “-omic approaches” and next-generation sequencing will improve our understanding of the pathogenesis and hopefully lead to better therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Incidentally Discovered Adrenal Mass
Young, W. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp065470 · Cited by 1,096
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationAdrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationTissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458
Self-citationExtent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis
Giordano, T. J., Thomas, D. G., Kuick, R., Lizyness, M., Misek, D. E., Smith, A. L., Sanders, D., Aljundi, R. T., Gauger, P. G., Thompson, N. W., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63846-1 · Cited by 383
de Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382 · cited 3×
“BUB1 and PINK1 High expression of BUB1 together with low expression of PINK1 (26) Separation of poor prognosis ACC from less aggressive tumors Micro RNAs Altered expression profiles (eg, high miR 483 5 p) possibly related to TARBP2 overexpression (29–31) Predictors of prognosis, miR 483 5 p in serum may serve as bioma…”
BackgroundKerkhofs, T. M. A., Verhoeven, R. H. A., Van der Zwan, J. M., Dieleman, J., Kerstens, M. N., Links, T. P., Van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 341
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
Self-citationHaak, H., Hermans, J., van de Velde, C., Lentjes, E., Goslings, B., Fleuren, G.-J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Szolar, D. H., Korobkin, M., Reittner, P., Berghold, A., Bauernhofer, T., Trummer, H., Schoellnast, H., Preidler, K. W., & Samonigg, H. (2005) · Radiology · doi:10.1148/radiol.2342031876 · Cited by 314
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.941 · Cited by 312
Approach to the patient with an adrenal incidentaloma
Nieman, L. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0457 · Cited by 290
Brix, D., Allolio, B., Fenske, W., Agha, A., Dralle, H., Jurowich, C., Langer, P., Mussack, T., Nies, C., Riedmiller, H., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.06.024 · Cited by 286
Self-citationGicquel, C., BERTAGNA, X. Y., Gaston, V., Coste, J., Louvel, A., Baudin, É., Bertherat, J. Y., Chapuis, Y., Duclos, J. M., Schlumberger, M. J., et al. (2001) · PubMed · Cited by 285
Boland, G. W. L., Dwamena, B. A., Jagtiani Sangwaiya, M., Goehler, A. G., Blake, M. A., Hahn, P. F., Scott, J. A., & Kalra, M. K. (2011) · Radiology · doi:10.1148/radiol.11100569 · Cited by 282
The optimal imaging of adrenal tumours: a comparison of different methods
Ilias, I., Sahdev, A., Reznek, R. H., Grossman, A. B., & Pacak, K. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0045 · Cited by 266
de Fraipont, F., El Atifi, M., Cherradi, N., Le Moigne, G., Defaye, G., Houlgatte, R., Bertherat, J., Bertagna, X., Plouin, P.-F., Baudin, E., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1075 · Cited by 261
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma
Fassnacht, M., Hahner, S., Polat, B., Koschker, A.-C., Kenn, W., Flentje, M., & Allolio, B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1007 · Cited by 259
Self-citationBlake, M. A., Cronin, C. G., & Boland, G. W. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.10.4547 · Cited by 253
High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors
Sbiera, S., Schmull, S., Assie, G., Voelker, H.-U., Kraus, L., Beyer, M., Ragazzon, B., Beuschlein, F., Willenberg, H. S., Hahner, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0653 · Cited by 242
Self-citationBaudin, E., Pellegriti, G., Bonnay, M., Penfornis, A., Laplanche, A., Vassal, G., & Schlumberger, M. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2 · Cited by 239
Berthon, A., Sahut-Barnola, I., Lambert-Langlais, S., de Joussineau, C., Damon-Soubeyrand, C., Louiset, E., Taketo, M. M., Tissier, F., Bertherat, J., Lefrançois-Martinez, A.-M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq029 · Cited by 239
Prognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236
Gicquel, C. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.6.1444 · Cited by 224
The Weiss system for evaluating adrenocortical neoplasms: 25 years later
Lau, S. K., & Weiss, L. M. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.03.010 · Cited by 223
Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma
Miller, B. S., Ammori, J. B., Gauger, P. G., Broome, J. T., Hammer, G. D., & Doherty, G. M. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0532-2 · Cited by 221
Lughezzani, G., Sun, M., Perrotte, P., Jeldres, C., Alasker, A., Isbarn, H., Budäus, L., Shariat, S. F., Guazzoni, G., Montorsi, F., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.007 · Cited by 215
Adrenocortical carcinoma is a Lynch syndrome-associated cancer
Raymond, V. M., Everett, J. N., Furtado, L. V., Gustafson, S. L., Jungbluth, C. R., Gruber, S. B., Hammer, G. D., Stoffel, E. M., Greenson, J. K., Giordano, T. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.0988 · Cited by 208
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189
Self-citationPreclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma
Barlaskar, F. M., Spalding, A. C., Heaton, J. H., Kuick, R., Kim, A. C., Thomas, D. G., Giordano, T. J., Ben-Josef, E., & Hammer, G. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1456 · Cited by 189
Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients
Chabre, O., Libé, R., Assie, G., Barreau, O., Bertherat, J., Bertagna, X., Feige, J.-J., & Cherradi, N. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0051 · Cited by 189
Porpiglia, F., Fiori, C., Daffara, F., Zaggia, B., Bollito, E., Volante, M., Berruti, A., & Terzolo, M. (2010) · European Urology · doi:10.1016/j.eururo.2010.01.036 · Cited by 188
Khan, T. S., Imam, H., Juhlin, C., Skogseid, B., Gröndal, S., Tibblin, S., Wilander, E., Öberg, K., & Eriksson, B. (2000) · Annals of Oncology · doi:10.1023/a:1008377915129 · Cited by 183
Faßnacht, M., Johanssen, S., Fenske, W. K., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C. F., Quinkler, M. O., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 182
Self-citationTömböl, Z., Szabó, P. M., Molnár, V., Wiener, Z., Tölgyesi, G., Horányi, J., Riesz, P., Reismann, P., Patócs, A., Likó, I., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0096 · Cited by 176
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma
Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182367ac3 · Cited by 176
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173
Self-citationHeaton, J. H., Wood, M. A., Kim, A. C., Lima, L. O., Barlaskar, F. M., Almeida, M. Q., Fragoso, M. C. B. V., Kuick, R., Lerario, A. M., Simon, D. P., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.05.026 · Cited by 173
Leboulleux, S., Dromain, C., Bonniaud, G., Aupérin, A., Caillou, B., Lumbroso, J., Sigal, R., Baudin, E., & Schlumberger, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1540 · Cited by 170
Sperone, P., Ferrero, A., Daffara, F., Priola, A., Zaggia, B., Volante, M., Santini, D., Vincenzi, B., Badalamenti, G., Intrivici, C., et al. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0281 · Cited by 167
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly
Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0103 · Cited by 167
Grubbs, E. G., Callender, G. G., Xing, Y., Perrier, N. D., Evans, D. B., Phan, A. T., & Lee, J. E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0716-x · Cited by 158
Park, B. K., Kim, C. K., Kim, B., & Lee, J. (2007) · Radiology · doi:10.1148/radiol.2433051978 · Cited by 155
The role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154 · cited 1×
“Based on the results of two recent studies in 45 and 154 patients with first recurrence (99, 100), we suggest the following approach (Figure 1B): surgery for recurrent ACC should be performed patients with a disease-free interval of more than 12 months, in whom a complete resection is feasible.”
ResultSelf-citationChortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154
Self-citationTreatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
Quinkler, M. O., Hahner, S., Wortmann, S., Johanssen, S., Adam, P., Ritte, C., Strasburger, C. J., Allolio, B., & Faßnacht, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2564 · Cited by 154
Self-citationVeytsman, I. G., Nieman, L. K., & Fojo, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2775 · Cited by 154
Ragazzon, B., Libé, R., Gaujoux, S., Assié, G., Fratticci, A., Launay, P., Clauser, E., Bertagna, X., Tissier, F., de Reyniès, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2014 · Cited by 152 · cited 1×
“mors are associated with an aggressive phenotype (13).”
BackgroundVolante, M., Bollito, E., Sperone, P., Tavaglione, V., Daffara, F., Porpiglia, F., Terzolo, M., Berruti, A., & Papotti, M. G. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03423.x · Cited by 150
Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Self-citationThe Weiss Score and Beyond—Histopathology for Adrenocortical Carcinoma
Papotti, M. G., Libé, R., Duregon, E., Volante, M., Bertherat, J. Y., & Tissier, F. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0088-0 · Cited by 148
Naing, A., LoRusso, P. M., Fu, S., Hong, D. S., Chen, H. X., Doyle, L. A., Phan, A. T., Habra, M. A., & Kurzrock, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.46 · Cited by 147
Berruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 146
Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Self-citationGaujoux, S., Tissier, F., Groussin, L., Libé, R., Ragazzon, B., Launay, P., Audebourg, A., Dousset, B., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0631 · Cited by 142
Gross, D. J., Munter, G., Bitan, M., Siegal, T., Gabizón, A., Weitzen, R., Merimsky, O., Ackerstein, A., Salmon, A. Y., Sella, A., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01124 · Cited by 136
Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0242 · Cited by 134 · cited 1×
“cently also introduced in the adjuvant setting (135).”
BackgroundSelf-citationBevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Self-citationBonnet, S., Gaujoux, S., Launay, P., Baudry, C., Chokri, I., Ragazzon, B., Libé, R., René-Corail, F., Audebourg, A., Vacher-Lavenu, M.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1885 · Cited by 133
Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas
Barreau, O., Assié, G., Wilmot-Roussel, H., Ragazzon, B., Baudry, C., Perlemoine, K., René-Corail, F., Bertagna, X., Dousset, B., Hamzaoui, N., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2993 · Cited by 132 · cited 1×
“CpG islands Hypermethylation with low expression of tumor suppressor genes (33, 34) Extensive hypermethylation negatively affects prognosis”
BackgroundLombardi, C. P., Raffaelli, M., De Crea, C., Boniardi, M., De Toma, G., Marzano, L. A., Miccoli, P., Minni, F., Morino, M., Pelizzo, M. R., et al. (2012) · Surgery · doi:10.1016/j.surg.2012.08.014 · Cited by 128
Mitotane has a strong and a durable inducing effect on CYP3A4 activity
van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0956 · Cited by 118
Contemporary Management of Adrenocortical Carcinoma
Zini, L., Porpiglia, F., & Faßnacht, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.062 · Cited by 117
Mackie, G. C., Shulkin, B. L., Ribeiro, R. C., Worden, F. P., Gauger, P. G., Mody, R. J., Connolly, L. P., Kunter, G., Rodriguez-Galindo, C., Wallis, J. W., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2612 · Cited by 115
Adjuvant and definitive radiotherapy for adrenocortical carcinoma
Sabolch, A., Feng, M., Griffith, K., Hammer, G., Doherty, G., & Ben-Josef, E. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.04.030 · Cited by 115
TP53 Germline Mutations in Adult Patients with Adrenocortical Carcinoma
Herrmann, L. J. M., Heinze, B., Fassnacht, M., Willenberg, H. S., Quinkler, M., Reisch, N., Zink, M., Allolio, B., & Hahner, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1982 · Cited by 109
Self-citationDuregon, E., Fassina, A., Volante, M., Nesi, G., Santi, R., Gatti, G., Cappellesso, R., Ciaramella, P. D., Ventura, L., Gambacorta, M., et al. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31828d387b · Cited by 108
Raymond, V. M., Else, T., Everett, J. N., Long, J. M., Gruber, S. B., & Hammer, G. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2198 · Cited by 105
Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel
Berruti, A., Faßnacht, M., Baudin, É., Hammer, G. D., Haak, H. R., Leboulleux, S., Skogseid, B. M., Allolio, B., & Terzolo, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5958 · Cited by 105
Self-citationHescot, S., Slama, A., Lombès, A., Paci, A., Remy, H., Leboulleux, S., Chadarévian, R., Trabado, S., Amazit, L., Young, J., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0368 · Cited by 104
Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma
Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Mueller, H. H., Skogseid, B. M., Leboulleux, S., Mantero, F., Haak, H. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2281 · Cited by 102
Self-citationHabra, M. A., Ejaz, S., Feng, L., Das, P., Deniz, F., Grubbs, E. G., Phan, A., Waguespack, S. G., Ayala-Ramirez, M., Jimenez, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2367 · Cited by 101
Operative management for recurrent and metastatic adrenocortical carcinoma
Datrice, N., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.23015 · Cited by 100
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors
Fonseca, A. L., Kugelberg, J., Starker, L. F., Scholl, U. I., Choi, M., Hellman, P., Åkerström, G., Westin, G., Lifton, R. P., Björklund, P., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21978 · Cited by 99
Adrenocortical carcinoma: effect of hospital volume on patient outcome
Lombardi, C. P., Raffaelli, M., Boniardi, M., Toma, G. D., Marzano, L. A., Miccoli, P., Minni, F., Morino, M., Pelizzo, M. R., Pietrabissa, A., et al. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0866-8 · Cited by 97
Inhibition of Adrenocortical Carcinoma Cell Proliferation by Steroidogenic Factor-1 Inverse Agonists
Doghman, M., Cazareth, J., Douguet, D., Madoux, F., Hodder, P., & Lalli, E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2163 · Cited by 94
Mir, M. C., Klink, J. C., Guillotreau, J., Long, J., Miocinovic, R., Kaouk, J. H., Simmons, M. N., Klein, E. A., Krishnamurthi, V., Campbell, S. C., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2760-1 · Cited by 92
Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models
Drelon, C., Berthon, A. S., Ragazzon, B., Tissier, F., Bandiera, R., Sahut‐Barnola, I., de Joussineau, C., Batisse‐Lignier, M., Lefrançois‐Martinez, A., Bertherat, J. Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044171 · Cited by 90
Duregon, E., Volante, M., Giorcelli, J., Terzolo, M., Lalli, E., & Papotti, M. G. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.07.025 · Cited by 90
Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells
Poli, G., Guasti, D., Rapizzi, E., Fucci, R., Canu, L., Bandinelli, A., Cini, N., Bani, D., Mannelli, M., & Luconi, M. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0150 · Cited by 89
Recommendation for standardized surgical management of primary adrenocortical carcinoma
Gaujoux, S., & Brennan, M. F. (2012) · Surgery · doi:10.1016/j.surg.2011.09.030 · Cited by 87
[131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Knoedler, P., Lang, K., Buck, A. K., Reiners, C., Allolio, B., & Schirbel, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2765 · Cited by 87
Self-citationFenske, W., Völker, H., Adam, P., Hahner, S., Johanssen, S., Wortmann, S., Schmidt, M., Morcos, M., Müller–Hermelink, H., Allolio, B., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0211 · Cited by 87
Self-citationProposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J., & Doherty, G. M. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0698-y · Cited by 84
Williams, A. R., Hammer, G. D., & Else, T. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1033 · Cited by 83
Almeida, M. Q., Soares, I. C., Ribeiro, T. C., Fragoso, M. C. B. V., Marins, L. V., Wakamatsu, A., Réssio, R. A., Nishi, M. Y., Jorge, A. A. L., Lerário, A. M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2040 · Cited by 82
FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma
Deandreis, D., Leboulleux, S., Caramella, C., Schlumberger, M. J., & Baudin, É. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0091-5 · Cited by 77
Zhang, H., Perrier, N. D., Grubbs, E. G., Sircar, K., Ye, Z., Lee, J. E., & Ng, C. S. (2011) · Clinical Radiology · doi:10.1016/j.crad.2011.03.023 · Cited by 75
Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma
Sasano, H., Suzuki, T., & Moriya, T. (2006) · Endocrine Pathology · doi:10.1007/s12022-006-0006-0 · Cited by 71
Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany
Johanssen, S., Hahner, S., Saeger, W., Quinkler, M. O., Beuschlein, F., Dralle, H., Haaf, M., Kroiß, M., Jurowich, C. F., Langer, P., et al. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0885 · Cited by 71
Self-citationResection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?
Gaujoux, S., Al‐Ahmadie, H. A., Allen, P. J., Gönen, M., Shia, J., D'Angelica, M. I., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & Jarnagin, W. R. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2358-7 · Cited by 70
Mauclère-Denost, S., Leboulleux, S., Borget, I., Paci, A., Young, J., Ghuzlan, A. A., Deandreis, D., Drouard, L., Tabarin, A., Chanson, P., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0557 · Cited by 70
Kerkhofs, T. M. A., Verhoeven, R. H. A., Bonjer, H. J., van Dijkum, E. J. M. N., Vriens, M. R., de Vries, J., van Eijck, C. H. J., Bonsing, B. A., van de Poll-Franse, L. V., Haak, H. R., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0142 · Cited by 67
Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma
Caramuta, S., Lee, L., Özata, D. M., Akçakaya, P., Xie, H. Y., Höög, A., Zedenius, J., Bäckdahl, M., Larsson, C., & Lui, W. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0098 · Cited by 65
A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma
Porpiglia, F., Miller, B. S., Manfredi, M., Fiori, C., & Doherty, G. M. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0095-1 · Cited by 64
Molecular epidemiology of adrenocortical tumors in southern Brazil
Custódio, G., Komechen, H., Figueiredo, F. R. O., Fachin, N. D., Pianovski, M. A. D., & Figueiredo, B. C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.10.019 · Cited by 63
Kemp, C. D., Ripley, R. T., Mathur, A., Steinberg, S. M., Nguyen, D. M., Fojo, T., & Schrump, D. S. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.05.013 · Cited by 63
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models
Mariniello, B., Rosato, A., Zuccolotto, G., Rubin, B., Cicala, M. V., Finco, I., Iacobone, M., Frigo, A. C., Fassina, A., Pezzani, R., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0337 · Cited by 63
Liver resection and ablation for metastatic adrenocortical carcinoma
Ripley, R. T., Kemp, C. D., Davis, J. L., Langan, R. C., Royal, R. E., Libutti, S. K., Steinberg, S. M., Wood, B. J., Kammula, U. S., Fojo, T., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1564-z · Cited by 62
Adjuvant Mitotane for Adrenocortical Cancer—A Recurring Controversy
Huang, H., & Fojo, T. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0579 · Cited by 62
Lehmann, T. P., Wrzesiński, T., & Jagodziński, P. P. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1244 · Cited by 62
Cazejust, J., de Baère, T., Auperin, A., Deschamps, F., Hechelhammer, L., Abdel-Rehim, M., Schlumberger, M. J., Leboulleux, S., & Baudin, É. (2010) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2010.05.020 · Cited by 61
Everolimus therapy for progressive adrenocortical cancer
Fraenkel, M., Gueorguiev, M., Barak, D. F., Salmon, A. Y., Grossman, A. B., & Gross, D. J. (2013) · Endocrine · doi:10.1007/s12020-013-9878-1 · Cited by 61
Tissier, F., Aubert, S., Leteurtre, E., Ghuzlan, A. A., Patey, M., Decaussin‐Petrucci, M., Doucet, L., Gobet, F., Hoang, C., Mazerolles, C., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825a6308 · Cited by 61
Conventional Imaging in Adrenocortical Carcinoma: Update and Perspectives
Young, W. F. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0089-z · Cited by 58
Current management options for recurrent adrenocortical carcinoma
Sidhu, S. B., Glover, A. R., Ip, Zhao, J., Soon, & Robinson (2013) · OncoTargets and Therapy · doi:10.2147/ott.s34956 · Cited by 54
Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P. (2011) · Endocrine Practice · doi:10.4158/ep10390.cr · Cited by 53
Samnotra, V., Vassilopoulou‐Sellin, R., Fojo, A. T., Oh, W. K., Larocca, R. V., Ernstoff, M. S., Memoli, V. A., Cole, B. F., Quinn, D. I., Simmons, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.15527 · Cited by 53
Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane
Stigliano, A., Cerquetti, L., Borro, M., Gentile, G., Bucci, B., Misiti, S., Piergrossi, P., Brunetti, E., Simmaco, M., & Toscano, V. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0003 · Cited by 51
[¹²³I]Iodometomidate imaging in adrenocortical carcinoma
Kreissl, M. C., Schirbel, A., Fassnacht, M., Haenscheid, H., Verburg, F. A., Bock, S., Saeger, W., Knoedler, P., Reiners, C., Buck, A. K., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3261 · Cited by 50
Self-citationVolante, M., Sperone, P., Bollito, E., Frangipane, E., Rosas, R., Daffara, F., Terzolo, M., Berruti, A., & Papotti, M. G. (2006) · Modern Pathology · doi:10.1038/modpathol.3800683 · Cited by 50
Xu, Y., Zhu, Y., Shen, Z., Sheng, J.-Y., He, H., Ma, G., Qi, Y., Zhao, J., Wu, Y., Rui, W., et al. (2011) · Endocrine · doi:10.1007/s12020-011-9502-1 · Cited by 49
Adrenocortical development and cancer: focus on SF-1
Lalli, E. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0143 · Cited by 48
Recent advances in adrenocortical carcinoma in adults
Bourdeau, I., MacKenzie-Feder, J., & Lacroix, A. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283602274 · Cited by 48
Mihai, R., Iacobone, M., Makay, Ö., Moreno, P., Frilling, A., Kraimps, J., Soriano, A., Villar, J. M., Barczyński, M., Durán, M., et al. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0876-6 · Cited by 47
Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma
Simon, D. P., Giordano, T. J., & Hammer, G. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2371 · Cited by 46
Metomidate-Based Imaging of Adrenal Masses
Hahner, S., & Sundín, A. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0093-3 · Cited by 44
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
D’Avolio, A., Francia, S. D., Basile, V., Cusato, J., Martino, F., Pirro, E., Piccione, F. M., Ardito, A., Zaggia, B., Volante, M., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283606cb2 · Cited by 42
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Hermsen, I. G. C., Gelderblom, H. A. J., Kievit, J., Romijn, J. A., & Haak, H. R. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0723 · Cited by 41
Metastatic Adrenocortical Carcinoma: Results of 56 Pulmonary Metastasectomies in 24 Patients
den Winkel, J. O., Pfannschmidt, J., Muley, T., Grünewald, C., Dienemann, H., Faßnacht, M., & Allolio, B. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.07.088 · Cited by 40
Self-citationNilubol, N., Zhang, L., Shen, M., Zhang, Y., He, M., Austin, C. P., & Kebebew, E. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-198 · Cited by 40
Kroiß, M., Reuss, M., Kühner, D., Johanssen, S., Beyer, M., Zink, M., Hartmann, M. F., Dhir, V., Wudy, S. A., Arlt, W., et al. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00027 · Cited by 38
Self-citationEffects of Mitotane on Gene Expression in the Adrenocortical Cell Line NCI-H295R: A Microarray Study
Zsippai, A., Szabó, D. R., Tömböl, Z., Szabó, P. M., Éder, K., Pállinger, É., Gaillard, R. C., Patócs, A., Tóth, S., Falus, A., et al. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.116 · Cited by 36
Mitotane treatment for adrenocortical carcinoma: an overview.
Francia, S. D., Ardito, A., Daffara, F., et al. (2012) · PubMed · Cited by 31
Jurowich, C. F., Faßnacht, M., Kroiß, M., Germer, C.-T., & Reibetanz, J. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0032-1331743 · Cited by 29
Dramatic Responses to Therapy in Rare Tumors
Chacon, R. D., Tossen, G., Loria, F. S., & Chacon, M. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.195 · Cited by 19
Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound
Bauditz, J., Quinkler, M. O., Beyersdorff, D., & Wermke, W. (2008) · Oncology Reports · doi:10.3892/or.19.5.1135 · Cited by 17
Ferrero, A., Sperone, P., Ardito, A., Rossi, G., Buono, S. D., Priola, A. M., Sergio Bracarda, A., Taberna, E., Terzolo, M., & Berruti, A. (2013) · PubMed · doi:10.3275/8334 · Cited by 15
Laparoscopic adrenalectomy for adrenocortical carcinoma: A medico-surgical perspective
Gaujoux, S., Bertherat, J. Y., Dousset, B. E., & Groussin, L. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.07.001 · Cited by 11
Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma
Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Leboulleux, S., Mantero, F., Haak, H. R., & Faßnacht, M. (2013) · Endocrine Abstracts · doi:10.1530/endoabs.32.p516 · Cited by 4
Self-citation
Cited by
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationFassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
Self-citationComprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.002 · Cited by 657
Self-citationNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Metadata
- Authors
- Fassnacht, M., Kroiss, M., & Allolio, B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12-01
- Volume
- 98
- Issue
- 12
- Pages
- 4551-4564
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1969237887
- Cited by
- 414
- References
- 137
- FWCI
- 38.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.